-
Tytuł:
-
Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic.
-
Autorzy:
-
Aschoff R; Department of Dermatology, Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Zimmermann N; Department of Dermatology, Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Beissert S; Department of Dermatology, Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Günther C; Department of Dermatology, Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
-
Źródło:
-
Dermatopathology (Basel, Switzerland) [Dermatopathology (Basel)] 2020 Dec 04; Vol. 7 (3), pp. 57-63. Date of Electronic Publication: 2020 Dec 04.
-
Typ publikacji:
-
Case Reports
-
Język:
-
English
-
Imprint Name(s):
-
Publication: [2020]- : Basel : MDPI
Original Publication: Basel : Karger AG, [2014]-
-
References:
-
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213. (PMID: 32215952)
JAMA Dermatol. 2020 Sep 1;156(9):998-1003. (PMID: 32584377)
JAAD Case Rep. 2020 Apr 18;6(6):489-492. (PMID: 32363225)
Annu Rev Med. 2017 Jan 14;68:297-315. (PMID: 27813875)
N Engl J Med. 2020 Jun 18;382(25):e102. (PMID: 32356626)
J Am Acad Dermatol. 2020 Jul;83(1):e61-e63. (PMID: 32339703)
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e667-e670. (PMID: 32534461)
JAMA Dermatol. 2020 Sep 1;156(9):1003. (PMID: 32584385)
JAMA Dermatol. 2019 Mar 1;155(3):342-346. (PMID: 30673078)
JAMA Dermatol. 2015 Apr;151(4):426-31. (PMID: 25517357)
Br J Dermatol. 2020 Oct;183(4):729-737. (PMID: 32562567)
J Am Acad Dermatol. 2020 Oct;83(4):1219-1222. (PMID: 32622895)
J Am Acad Dermatol. 2020 Sep;83(3):e269-e270. (PMID: 32565206)
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e291-e293. (PMID: 32330334)
Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026)
JAMA Dermatol. 2020 Sep 1;156(9):992-997. (PMID: 32584397)
Br J Dermatol. 2020 Oct;183(4):778-780. (PMID: 32585767)
Sci Immunol. 2016 Oct 21;1(4):. (PMID: 27872905)
Int J Dermatol. 2020 Jun;59(6):739-743. (PMID: 32329897)
Nat Rev Drug Discov. 2017 Dec;16(12):843-862. (PMID: 29104284)
Science. 2020 Aug 7;369(6504):718-724. (PMID: 32661059)
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e346-e347. (PMID: 32330324)
-
Grant Information:
-
369799452 - TRR237 German Research Foundation
-
Contributed Indexing:
-
Keywords: SARS-CoV-2; chilblain; type I interferon
-
Entry Date(s):
-
Date Created: 20201209 Latest Revision: 20201229
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC7768511
-
DOI:
-
10.3390/dermatopathology7030010
-
PMID:
-
33291622
-
Contemporarily to the new SARS-CoV-2 mediated COVID-19 pandemic, a rise in patients with acral chilblain lesions has been described. They manifest late after mild disease or asymptomatic exposure to SARS-CoV-2. Their pathogenic evolution is currently unknown. In biopsies from three patients with acral partially ulcerating chilblain lesions that occurred associated to the COVID-19 pandemic, we analysed the expression of type I interferon induced proteins and signal transduction kinases. Histology demonstrated perivascular and periadnexal lymphohistiocytic infiltrates and endothelial dominated MxA-staining, as well as pJAK1 activation. Our findings demonstrate induction of the type I IFN pathway in lesional sections of COVID-19-associated chilblain-like lesions. This may indicate a local antiviral immune activation status associated with preceding exposure to SARS-CoV-2.